Phospho-IRAK1 (Ser376) Antibody

What is IRAK1 and why is the Ser376 phosphorylation site significant?

IRAK1 (Interleukin-1 Receptor-Associated Kinase 1) is a serine/threonine kinase that plays a critical role in inflammatory signaling pathways. It becomes associated with the interleukin-1 receptor (IL1R) upon stimulation and is partially responsible for IL1-induced upregulation of the transcription factor NF-kappa B . The Ser376 phosphorylation site is particularly significant because it represents a key regulatory modification that influences IRAK1's function in signaling cascades. Phosphorylation at this residue occurs in response to inflammatory stimuli and is crucial for the propagation of downstream signaling events that lead to inflammatory gene expression . Research has demonstrated that inhibition of IRAK1 Ser376 phosphorylation can attenuate IL-1β-induced activation of NF-κB in human chondrocytes, highlighting its importance in inflammatory processes related to conditions such as osteoarthritis .

How does a Phospho-IRAK1 (Ser376) antibody differ from a pan-IRAK1 antibody?

A Phospho-IRAK1 (Ser376) antibody specifically recognizes IRAK1 protein only when it is phosphorylated at the Serine 376 residue, providing crucial information about the activation state of the protein . In contrast, a pan-IRAK1 antibody detects the total IRAK1 protein regardless of its phosphorylation status. The specificity of the phospho-specific antibody allows researchers to monitor dynamic changes in IRAK1 activation in response to various stimuli or experimental conditions. When designing experiments, it's important to use both antibodies in parallel to determine the proportion of phosphorylated IRAK1 relative to total IRAK1, which provides insight into the degree of pathway activation. This approach enables more precise interpretation of signaling events where post-translational modifications, rather than changes in total protein levels, dictate functional outcomes.

What are the optimal storage conditions for maintaining Phospho-IRAK1 (Ser376) antibody activity?

For short-term storage (up to several weeks), Phospho-IRAK1 (Ser376) antibodies should be stored at 4°C in an appropriate buffer system that typically includes 0.01M TBS (pH 7.4) with 1% BSA and glycerol . For long-term storage, aliquoting the antibody and storing it at -20°C is recommended to maintain specificity and activity . It is crucial to avoid repeated freeze-thaw cycles as these can denature the antibody and compromise its performance in experimental applications. A systematic study of antibody stability demonstrated that phospho-specific antibodies are particularly sensitive to temperature fluctuations compared to their non-phospho-specific counterparts. When preparing working dilutions, only remove the amount needed for immediate use, and allow the antibody to equilibrate to room temperature before opening the vial to prevent condensation, which can introduce contaminants and accelerate degradation.

What are the validated applications for Phospho-IRAK1 (Ser376) antibody in research?

Phospho-IRAK1 (Ser376) antibodies have been validated for multiple research applications that provide insights into IRAK1 activation status across various experimental systems. Based on the literature, the following applications have been successfully demonstrated:

Each application requires specific optimization steps, including blocking endogenous peroxidase activity with 3% hydrogen peroxide and using appropriate blocking buffers to minimize non-specific binding . When performing IHC, overnight incubation at 4°C typically yields the best signal-to-noise ratio for detecting phosphorylated epitopes in tissue sections .

How should I design experiments to assess IRAK1 Ser376 phosphorylation dynamics?

To effectively assess IRAK1 Ser376 phosphorylation dynamics, a time-course experiment following stimulation with IL-1β or other TLR ligands is recommended. Begin by establishing baseline phosphorylation levels in your experimental system, then measure changes at multiple time points (typically 5, 15, 30, 60, 120 minutes) after stimulation . This approach allows for the capture of both rapid and sustained phosphorylation events.

It is essential to include appropriate controls:

• Unstimulated cells to establish baseline

• Cells treated with phosphatase inhibitors to preserve phosphorylation status

• Cells pre-treated with specific IRAK inhibitors as negative controls

• Parallel detection of total IRAK1 to normalize phosphorylation signals

For signal quantification, densitometric analysis of western blots should be performed, normalizing phospho-IRAK1 (Ser376) signal to total IRAK1 levels. This normalization accounts for potential variations in total protein expression between samples. In studies examining the inhibitory effects of compounds on IRAK1 phosphorylation, such as delphinidin's effect on IL-1β-induced IRAK1 activation, dose-dependent treatments should be conducted to establish IC50 values . Additionally, complementary approaches such as mass spectrometry-based phosphoproteomics can provide unbiased confirmation of site-specific phosphorylation events .

What are the optimal sample preparation protocols for detecting Phospho-IRAK1 (Ser376) in different experimental systems?

The detection of phosphorylated proteins requires careful sample preparation to preserve phosphorylation status while minimizing background. For different experimental systems, the following protocols are recommended:

For cell culture lysates:

• Harvest cells rapidly in ice-cold PBS containing phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4)

• Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and freshly added protease and phosphatase inhibitor cocktails

• Sonicate briefly (3-5 pulses) to shear DNA and reduce viscosity

• Centrifuge at 14,000 × g for 15 minutes at 4°C and collect supernatant

• Quantify protein concentration and proceed immediately to analysis or flash-freeze aliquots

For tissue samples:

• Collect tissues and immediately flash-freeze in liquid nitrogen

• Homogenize frozen tissue in ice-cold RIPA buffer supplemented with phosphatase inhibitors using a tissue homogenizer

• Incubate on ice for 30 minutes with occasional vortexing

• Centrifuge at 14,000 × g for 20 minutes at 4°C

• For paraffin-embedded tissues, optimized antigen retrieval is critical - use citrate buffer (0.01M, pH 6.0) with boiling for 15 minutes

For phosphoproteomics analysis:

• Extract proteins using urea-based lysis buffer (8M urea, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, phosphatase inhibitors)

• Reduce and alkylate proteins prior to trypsin digestion

• Enrich for phosphopeptides using titanium dioxide (TiO2) or immobilized metal affinity chromatography (IMAC)

• Analyze enriched phosphopeptides by liquid chromatography-mass spectrometry (LC-MS/MS)

The preservation of phosphorylation status is particularly important when working with transient modifications like IRAK1 Ser376 phosphorylation. Always maintain samples at 4°C during processing and minimize the time between sample collection and analysis or freezing.

Why might I observe weak or no signal when using Phospho-IRAK1 (Ser376) antibody in Western blots?

Several factors can contribute to weak or absent signals when detecting Phospho-IRAK1 (Ser376):

• Rapid dephosphorylation post-stimulation: IRAK1 phosphorylation can be transient, with rapid turnover. Ensure cells are lysed quickly after stimulation and that phosphatase inhibitors (such as sodium orthovanadate, sodium fluoride, and β-glycerophosphate) are included in all buffers.

• Insufficient stimulation: Ensure adequate activation of the IL-1R/TLR pathway. Based on research protocols, stimulation with IL-1β at 10 ng/ml for at least 5-15 minutes is typically required to observe robust IRAK1 Ser376 phosphorylation .

• Antibody specificity issues: The antibody may recognize the phospho-epitope only in certain species or contexts. Confirm that your antibody has been validated for your specific experimental system. The literature indicates that some phospho-IRAK1 antibodies have been validated in mouse and human systems .

• Protein degradation during sample preparation: IRAK1 undergoes rapid ubiquitination and degradation following activation. Include proteasome inhibitors (MG132) in your lysis buffer to preserve polyubiquitinated forms.

• Suboptimal transfer conditions: Phosphorylated proteins, especially those of higher molecular weight, may require extended transfer times or modified transfer conditions. Consider using wet transfer instead of semi-dry transfer systems for improved efficiency.

If problems persist, a phospho-protein enrichment step prior to Western blotting can significantly improve detection sensitivity. Commercial phosphoprotein enrichment kits using metal affinity chromatography can increase the concentration of phosphorylated proteins in your sample by 10-20 fold, enhancing detection of low-abundance phosphorylated species like IRAK1.

How can I validate the specificity of Phospho-IRAK1 (Ser376) antibody staining in my experimental system?

Validating antibody specificity is crucial for ensuring reliable results, particularly for phospho-specific antibodies. Implement the following comprehensive validation strategy:

• Positive and negative controls:

  • Use cell lysates from cells treated with known IRAK1 activators (IL-1β, LPS) as positive controls

  • Include lysates from cells treated with IRAK1/4 inhibitors as negative controls

  • If possible, use IRAK1 knockout cells or IRAK1 knockdown (shRNA) samples as gold-standard negative controls

• Dephosphorylation controls:

  • Treat half of your positive control sample with lambda phosphatase to remove phosphate groups

  • The signal should disappear in the dephosphorylated sample when probed with phospho-specific antibody

• Peptide competition assay:

  • Pre-incubate your antibody with excess phospho-peptide containing the Ser376 epitope

  • This should abolish specific binding in your assay

• Site-directed mutagenesis:

  • Express wild-type IRAK1 and IRAK1-S376A mutant (where serine is replaced with alanine to prevent phosphorylation)

  • The antibody should recognize only the wild-type protein after stimulation

• Correlation with functional readouts:

  • Verify that IRAK1 Ser376 phosphorylation correlates with downstream events such as NF-κB activation

  • Use NF-κB reporter assays or measure phosphorylation of downstream targets like IKKα/β

In published studies, researchers have validated phospho-IRAK1 antibodies by demonstrating increased phosphorylation after IL-1β stimulation and reduced phosphorylation following treatment with inhibitors such as delphinidin . Additionally, correlation with functional outcomes like COX-2 expression and PGE2 production has provided evidence for the biological relevance of the detected phosphorylation .

What are the most common cross-reactivity issues with Phospho-IRAK1 (Ser376) antibodies and how can I address them?

Phospho-specific antibodies may exhibit cross-reactivity with similar phosphorylated epitopes in other proteins, particularly within conserved kinase domains. For Phospho-IRAK1 (Ser376) antibodies, several approaches can mitigate cross-reactivity concerns:

• Identify potential cross-reactive targets:

  • Perform a BLAST search of the immunogenic peptide sequence used to generate the antibody

  • Common cross-reactive candidates include other IRAK family members (IRAK2, IRAK4) and related kinases with similar phosphorylation motifs

• Implement rigorous experimental controls:

  • Include IRAK1 knockdown or knockout samples to identify non-specific bands

  • Test the antibody in cells overexpressing IRAK1 versus empty vector controls

  • Compare multiple Phospho-IRAK1 (Ser376) antibodies from different sources or raised against different epitopes

• Optimize immunoblotting conditions:

  • Increase the dilution of primary antibody to reduce non-specific binding

  • Extend washing steps between antibody incubations

  • Use casein-based blocking solutions instead of BSA when high background is observed

  • Consider using specialized low-background membranes for phosphoprotein detection

• Employ confirmation strategies:

  • Verify results using orthogonal techniques such as mass spectrometry-based phosphoproteomics

  • Use phospho-tag SDS-PAGE, which can separate phosphorylated from non-phosphorylated proteins based on mobility shifts

  • Confirm with in vitro kinase assays using purified IRAK1 protein

In research settings where absolute specificity is required, such as when studying novel IRAK1 phosphorylation mechanisms or developing IRAK1-targeted therapeutics, consider using a combination of antibody-based detection and mass spectrometry validation. This approach has been employed in studies examining IRAK1 phosphorylation in acute myeloid leukemia, where multiple analytical techniques were used to confirm specificity .

How does IRAK1 Ser376 phosphorylation relate to other phosphorylation sites on IRAK1, and what is their hierarchical relationship?

IRAK1 contains multiple phosphorylation sites that coordinate to regulate its activity and interactions within signaling complexes. The relationship between Ser376 phosphorylation and other phosphorylation events represents a complex regulatory network:

The key phosphorylation sites on IRAK1 include:

• Thr209: Critical for IRAK1 activation and known to be constitutively phosphorylated in certain disease states

• Ser376: Important for downstream signaling to NF-κB pathways

• Thr387: Involved in IRAK1 autophosphorylation

• Ser568: Contributes to IRAK1 kinase activity

Research has demonstrated a potential hierarchical relationship between these sites. For example, studies of the IRAK1 Phe196Ser mutation in primary effusion lymphoma (PEL) showed that this mutation, which introduces a novel potential phosphorylation site, affects the phosphorylation status of Thr209 . The mutation was associated with constitutive phosphorylation at T209 even in the absence of exogenous stimuli, suggesting an interdependent relationship between phosphorylation events .

Additionally, IRAK1 Ser376 phosphorylation appears to be downstream of initial activation events but upstream of interactions with scaffold proteins and E3 ubiquitin ligases such as Pellino isoforms . In experimental systems, phosphorylation of IRAK1 enhances its interaction with Pellino isoforms and dramatically increases Pellino's E3 ubiquitin ligase activity .

To fully understand the sequential nature of these phosphorylation events, time-course studies using phospho-specific antibodies against multiple sites simultaneously would be valuable. Current research suggests that initial phosphorylation events (possibly at Thr209) trigger conformational changes that expose additional sites (including Ser376) for subsequent phosphorylation, creating a cascade of modifications that progressively alter IRAK1's functional properties and interaction capabilities.

What is the role of IRAK1 Ser376 phosphorylation in modulating the interaction between IRAK1 and Pellino in signaling pathways?

IRAK1 Ser376 phosphorylation plays a critical role in mediating the functional interaction between IRAK1 and Pellino proteins, which are key regulators of inflammatory signaling:

• Enhancement of protein-protein interactions: Phosphorylation of IRAK1, including at Ser376, significantly enhances its interaction with Pellino isoforms. Research has demonstrated that wild-type IRAK1 interacts more strongly with Pellino isoforms compared to catalytically inactive IRAK1, suggesting that phosphorylation events strengthen this protein-protein interaction .

• Activation of Pellino E3 ubiquitin ligase activity: IRAK1-mediated phosphorylation of Pellino isoforms dramatically enhances their E3 ubiquitin ligase activity . This phosphorylation-dependent activation represents a key regulatory mechanism in the signaling cascade.

• Ubiquitination cascade initiation: The IRAK1-Pellino interaction facilitates the K63-linked polyubiquitination of IRAK1, which serves as a platform for the recruitment of additional signaling components, including TRAF6, TAK1, and IKK complexes.

• Signal diversification: Different patterns of IRAK1 phosphorylation, including at Ser376, may differentially affect its interaction with different Pellino isoforms (Pellino 1, 2, and 3), potentially contributing to signal diversification downstream of IL-1R/TLR activation.

Experimental evidence from in vitro studies shows that IRAK1 can directly phosphorylate Pellino isoforms, and this phosphorylation strikingly enhances their E3 ubiquitin ligase activity . This suggests a model where IRAK1 phosphorylation (including at Ser376) strengthens its interaction with Pellino, bringing the proteins into proximity and allowing IRAK1 to phosphorylate Pellino, thus activating its E3 ligase function.

The physiological significance of this interaction is highlighted by studies showing that disruption of the IRAK1-Pellino axis can inhibit NF-κB activation and reduce inflammatory gene expression. In conditions such as osteoarthritis, compounds like delphinidin that inhibit IRAK1 Ser376 phosphorylation also reduce downstream NF-κB activation, suggesting therapeutic potential in targeting this specific phosphorylation event .

How do mutations or post-translational modifications near the Ser376 site affect IRAK1 function in pathological conditions?

Mutations and post-translational modifications near the Ser376 site can profoundly impact IRAK1 function, particularly in disease states:

• IRAK1 Phe196Ser mutation in cancer: A striking example is the Phe196Ser mutation identified in nearly 100% of primary effusion lymphoma (PEL) cases . This mutation:

  • Introduces a novel potential phosphorylation site

  • Is associated with constitutive phosphorylation of IRAK1 at T209

  • Appears to be a gain-of-function mutation that enhances IRAK1 signaling

  • Is required for PEL survival, suggesting it functions as a cell-autonomous oncogenic driver

• Proximity effects on Ser376 phosphorylation: The Phe196 residue is part of a conserved phenylalanine triad in IRAK1, and its mutation to serine significantly alters the protein's structural and functional properties . The proximity of this mutation to the Ser376 phosphorylation site suggests potential conformational changes that could affect accessibility of Ser376 to kinases or phosphatases.

• Impact on protein-protein interactions: Mutations near Ser376 can alter IRAK1's interaction with regulatory partners. For example, the IRAK1 Phe196Ser variant demonstrates different biochemical properties than wild-type IRAK1, potentially affecting its interaction with MyD88, IRAK4, or viral proteins in the context of virus-associated lymphomas .

• Therapeutic implications: Understanding how specific mutations affect IRAK1 phosphorylation and function has direct therapeutic relevance. For instance, IRAK inhibitors have entered clinical trials for various cancers, including those with aberrant IRAK1 activation . The effectiveness of these inhibitors may vary depending on the specific mutations or post-translational modifications present in individual patients' tumors.

Research in hematological malignancies has demonstrated that IRAK1 inhibition shows promise against acute myeloid leukemia (AML), even in cases resistant to other targeted therapies such as FLT3 inhibitors . The pacritinib multikinase inhibitor, which targets IRAK1 among other kinases, has shown efficacy in AML models at clinically achievable concentrations, highlighting the potential of targeting IRAK1 phosphorylation in cancer therapy .

How is IRAK1 Ser376 phosphorylation implicated in inflammatory diseases, and what biomarker potential does it have?

IRAK1 Ser376 phosphorylation serves as a critical node in inflammatory signaling networks and has emerging relevance as a potential biomarker in several inflammatory conditions:

• Role in osteoarthritis (OA): Research has demonstrated that IL-1β-induced IRAK1 Ser376 phosphorylation is elevated in human chondrocytes from OA patients and correlates with disease progression . This phosphorylation event leads to:

  • Increased activation of NF-κB signaling

  • Enhanced expression of cyclooxygenase-2 (COX-2)

  • Elevated production of prostaglandin E2 (PGE2), a key mediator of cartilage degradation and pain

• Biomarker applications:

  • Disease activity monitoring: Levels of phosphorylated IRAK1 (Ser376) in synovial fluid or blood may correlate with inflammatory activity in conditions like rheumatoid arthritis

  • Treatment response prediction: Baseline levels of IRAK1 Ser376 phosphorylation might predict responsiveness to anti-inflammatory therapies

  • Stratification of patient populations: Different patterns of IRAK1 phosphorylation could help identify patient subgroups who might benefit from specific targeted therapies

• Technical considerations for biomarker development:

  • Sample type: Tissue biopsies provide direct assessment but are invasive; circulating immune cells may serve as surrogate markers

  • Detection methods: Phospho-flow cytometry allows single-cell resolution measurement of IRAK1 phosphorylation in specific immune cell populations

  • Normalization strategies: Ratio of phospho-IRAK1 to total IRAK1 provides more reliable results than absolute phosphorylation levels

• Validation studies needed:

  • Longitudinal assessment correlating IRAK1 Ser376 phosphorylation with disease progression

  • Comparison with established inflammatory biomarkers (CRP, ESR, cytokine profiles)

  • Standardization of detection protocols for clinical laboratory implementation

The inhibition of IRAK1 Ser376 phosphorylation by compounds like delphinidin correlates with reduced inflammatory signaling and decreased production of cartilage-degrading molecules, suggesting that this phosphorylation event could serve as both a biomarker and therapeutic target in inflammatory arthritis . Current research indicates that monitoring changes in IRAK1 phosphorylation status may provide more immediate information about treatment efficacy than conventional clinical measures, potentially allowing for more rapid therapeutic adjustments.

What therapeutic strategies target IRAK1 Ser376 phosphorylation in cancer and inflammatory diseases?

Multiple therapeutic approaches targeting IRAK1 Ser376 phosphorylation and related signaling pathways are under investigation for cancer and inflammatory conditions:

• Direct IRAK1 kinase inhibitors:

  • Pacritinib: A multikinase inhibitor that effectively inhibits IRAK1 activity at clinically relevant concentrations (IC50 in nanomolar range)

  • IRAK1/4 inhibitors: Small molecules that block the catalytic activity of both IRAK1 and its upstream activator IRAK4

  • Selective IRAK1 inhibitors: Compounds designed to specifically target IRAK1 while sparing other IRAK family members

• Natural compounds with IRAK1-inhibitory activity:

  • Delphinidin: An anthocyanidin that inhibits IL-1β-induced phosphorylation of IRAK1 Ser376 in human chondrocytes, reducing NF-κB activation and inflammatory gene expression

  • Other plant-derived polyphenols: Several have shown ability to modulate IRAK1 signaling through direct or indirect mechanisms

• Therapeutic outcomes in different disease contexts:

• Combination therapy approaches:

  • IRAK1 inhibitors + JAK inhibitors: Targeting multiple nodes in overlapping inflammatory pathways

  • IRAK1 inhibitors + conventional chemotherapy: Sensitizing resistant cancer cells by blocking pro-survival signaling

  • IRAK1 inhibitors + immunotherapy: Potential to enhance immune response by modulating inflammatory signaling

Clinical studies have demonstrated that pacritinib, which inhibits IRAK1 among other kinases, achieves steady-state free drug concentrations of approximately 200-250 nM in patients, which is sufficient to inhibit IRAK1 activity . This provides a pharmacological proof-of-concept for targeting IRAK1 in clinical settings. Furthermore, inhibition of IRAK1 has shown efficacy in AML cell lines harboring a variety of genetic abnormalities, not limited to those with FLT3 or JAK2 mutations, suggesting broad therapeutic potential .

How can Phospho-IRAK1 (Ser376) antibodies be used to evaluate the efficacy of IRAK1-targeted therapeutics in preclinical and clinical studies?

Phospho-IRAK1 (Ser376) antibodies serve as critical tools for evaluating the efficacy of IRAK1-targeted therapeutics throughout the drug development process:

• Preclinical target engagement studies:

  • Dose-response assessment: Quantifying the relationship between inhibitor concentration and reduction in IRAK1 Ser376 phosphorylation

  • Time-course analysis: Determining the duration of IRAK1 inhibition following single or multiple doses

  • Pharmacodynamic biomarker development: Establishing IRAK1 Ser376 phosphorylation as a measurable indicator of drug activity

• Ex vivo assays for clinical samples:

  • Fresh blood samples from patients can be stimulated with IL-1β or TLR ligands ex vivo and treated with IRAK1 inhibitors to assess individual responsiveness

  • Phospho-flow cytometry using Phospho-IRAK1 (Ser376) antibodies enables single-cell analysis of inhibitor effects across different immune cell populations

  • Comparison of pre- and post-treatment samples allows direct assessment of in vivo target engagement

• Correlation with functional outcomes:

  • IRAK1 Ser376 phosphorylation status can be correlated with downstream signaling events such as NF-κB activation using Trans-AM ELISA assays

  • Expression levels of IRAK1-dependent genes can be measured to confirm the functional consequences of inhibiting IRAK1 phosphorylation

  • In cancer studies, correlation between IRAK1 inhibition and metrics such as cell viability, apoptosis (measured by annexin V staining), and in vivo tumor burden provides comprehensive efficacy assessment

• Implementation in clinical trials:

  • Patient stratification: Pre-treatment levels of IRAK1 Ser376 phosphorylation may identify patients most likely to benefit from IRAK1-targeted therapy

  • Early response assessment: Changes in IRAK1 phosphorylation after initial doses may predict subsequent clinical response

  • Resistance monitoring: Re-emergence of IRAK1 phosphorylation despite continued treatment may indicate development of resistance mechanisms

In xenograft studies of AML, researchers have used doxycycline-inducible IRAK1 shRNA systems to demonstrate the dependence of leukemia cells on IRAK1 signaling . Similar approaches using Phospho-IRAK1 (Ser376) antibodies could be employed to monitor the effects of pharmacological IRAK1 inhibition in patient-derived xenograft models, providing translational insights that bridge preclinical and clinical development. The combination of phospho-specific antibody-based assays with functional readouts provides a comprehensive assessment of IRAK1 inhibitor efficacy, supporting rational drug development and precision medicine approaches.